l 2025 and employs over 7,500 people across 65 manufacturing sites and 85 offices worldwide.
It sits in the specialty industrial machinery segment of the broader industrial automation industry, an arena dominated by large incumbents like Siemens, ABB, and Rockwell Automation. ATS competes by staying focused on specific end markets, offering end-to-end turnkey solutions, and leaning into high-growth verticals like life sciences (e.g., GLP-1 autoinjector assembly) and clean energy (e.g., nuclear refurbishment).
That smaller scale (vs. the giants) can limit pricing power. But ATS’s flexible engineering model and targeted acquisitions (e.g., Paxiom, Heidolph, and IT.ACA) have strengthened its position in niche, high-complexity projects and helped deepen client relationships.
Recent Performance
Over the past 12 months ending January 9, 2026, ATS’s share price rose 4.6%, from CAD 27.54 at the end of 2024 to CAD 28.80 (USD 28.80) today.
For context, the S&P 500 gained 16.4% in calendar 2025, powered by strong performance in large-cap US equities. ATS lagged that run due to sector-specific headwinds (including residual effects of the EV customer settlement), a downturn in its transportation segment, and investors staying cautious on industrial capex.
Fundamental Analysis
Growth Prospects
ATS generated a five-year adjusted revenue CAGR of 13.4% through fiscal 2025, fueled by strong delivery in life sciences and energy.
In Q4 2025, life sciences revenues rose 11.1% year-over-year and energy revenues climbed 38.7%, while transportation fell 69.2% after earlier peaks tied to EV projects.
The order backlog hit CAD 2.14 billion (+19.3% YoY) at March 31, 2025. Add in Q2 2026 organic growth of 12.6%, and the setup supports mid-teens revenue growth in fiscal 2026.
Potential upside could come from wider adoption of digital factory software and deeper penetration in high-growth verticals.
Quality & Moat
ATS is running with a net cash position, with net debt/EBITDA of 0.0 vs. the Industrials sector average of 1.16. That gives it flexibility and keeps leverage risk low (based on the ratio provided).
Profitability is improving, but it’s still a work in progress. ATS delivered an adjusted operating margin of 10.5% in fiscal 2025, and management targets a 15% margin over the medium term — aiming to get there through operating leverage and more standardization.
Its engineering-to-order model, broad global footprint, and specialized know-how create a moderate moat in complex automation niches.
Management has also stepped up investor communication and launched a CAD 15 million restructuring to sharpen focus on core growth areas — signaling disciplined capital allocation and the ability to move quickly when needed.
Valuation
ATS trades at a discount to the broader market on headline multiples. Its current P/E (LTM) is about 20.4x and its adjusted P/E is 17.6x, versus a forward P/E of 26.3x for the broader market.
On sales, ATS sits at about 1.5x trailing revenue (P/S). That’s below larger automation peers like Rockwell and Schneider, which often trade around 2.5–3.5x.
That discount lines up with what investors have been worried about: recent earnings volatility and higher project execution risk. Still, improving backlog and margin initiatives may support a valuation that sits above smaller pure-play integrators.
Market Sentiment
Institutional investors own about 76% of ATS’s shares, showing plenty of professional interest.
Short interest is around 2.7% of float, with roughly 21.5 days to cover — and that’s down from prior months, which suggests bearish positioning has eased.
Technically, the stock is trading above its 50-day moving average (CAD 26.97) and 200-day moving average (CAD 27.63). RSI sits at a neutral 56.7, pointing to a market that’s neither stretched nor beaten up.
Analyst sentiment is mixed-to-positive. Several regional banks rate ATS as a buy, with price targets implying 20–30% upside. Coverage is light, and the overall consensus spans “Hold” to “Buy” across platforms.
Key Risks
- Cyclical End Markets: ATS’s revenues are tied to global manufacturing capex cycles — especially in transportation and consumer goods — which can make the topline vulnerable in an economic downturn.
- Execution Risk: Big, custom automation projects are complicated to engineer and integrate. Cost overruns or delays (as seen in the prior EV settlement) can hit margins in a meaningful way.
- Competition: Bigger incumbents like Siemens, Rockwell, and ABB bring scale and broader product portfolios, which can crank up pricing pressure across key geographies and segments.
- Foreign Exchange: About 40% of revenues and costs are in non-CAD currencies. If FX moves the wrong way and hedging doesn’t fully offset it, reported results can take a hit.
- Volatility & Beta: The stock’s 34% volatility vs. a 21% market average, plus a beta of 1.15, means it tends to swing more than the market — and that can amplify downside in risk-off periods.
Bull Case
- Backlog Visibility: A CAD 2.14 billion order backlog at Q4 2025 supports mid-teens revenue growth and gives margin expansion a stronger foundation for fiscal 2026.
- High-Growth Verticals: ATS is specialized in life sciences (GLP-1 auto-injectors, radiopharma) and nuclear/energy. Those markets can grow faster than broad industrial capex, adding secular tailwinds.
- Net Cash Position: Net debt/EBITDA of 0.0 gives ATS balance sheet flexibility to invest in technology, pursue bolt-on acquisitions, and return capital via buybacks.
- Valuation Discount: The stock trades at about 17.6x adjusted P/E vs. roughly 26x for the market average, and peers typically trade around 2.5x P/S (vs. ATS at ~1.5x). If execution steadies, that gap could narrow.
- Margin Expansion Initiatives: Restructuring and standardization efforts — plus a growing mix of recurring services — could push adjusted operating margins toward the 15% target.
Bear Case
- EV Headwinds Remain: Uncertainty around EV customer relationships, and the risk of further project re-pricing, could keep pressure on margins and cash flows.
- Transportation Segment Weakness: Transportation revenues fell 69% in Q4 2025, underlining how volatile this segment can be. Without a rebound, it could weigh on growth and utilization.
- Macro Slowdown Risk: If global manufacturing slows or financing tightens, customers could postpone or cancel projects, which would hurt order bookings.
- Competitive Pressure: Large automation players could undercut ATS on price, or bundle digital/IoT offerings, which may reduce ATS’s win rates on bigger contracts.
- Limited Analyst Coverage: Light coverage can increase information gaps. If guidance is missed or surprises land badly, the share price could react more sharply than usual.
On Our Radar
- Q3 FY2026 Earnings (Feb 2026): Management will report Q3 results for the quarter ended December 31, 2025, likely around February 25, 2026. Expect updated guidance and more detail on project execution.
- CEO Transition (Jan 14, 2026): Doug Wright will officially step into the CEO role. Investors will pay close attention to his early messaging, especially around capital allocation priorities.
- Investor Day (May 2026): ATS’s annual investor day is expected in May 2026, which should give more detail on long-term targets, market investment plans, and technology roadmaps.
- Major Life Sciences Contracts: Potential awards for GLP-1 assembly lines with leading pharma partners in H2 2026 could be a meaningful catalyst for the life sciences segment.
Investment Conclusion
ATS trades at a discount to both the broader market and large automation peers. It has a strong backlog, exposure to secular growth markets, and a net-cash balance sheet.
That said, you’re not buying a “set it and forget it” story. The business is still exposed to cyclical manufacturing demand, project execution risk, and tough competition.
For long-term investors who want exposure to automation and life sciences growth, the current valuation could look appealing — as long as they’re comfortable with execution volatility and macro sensitivity. Investors who are more focused on near-term margin pressure, or who dislike the uncertainty that comes with limited analyst coverage, may prefer to wait for clearer operational traction before adding exposure.
| Help us improve Stock Snapshots — share your feedback.
